AR050184A1 - Inhibidores macrociclicos de beta-secretasa - Google Patents
Inhibidores macrociclicos de beta-secretasaInfo
- Publication number
- AR050184A1 AR050184A1 ARP050103099A ARP050103099A AR050184A1 AR 050184 A1 AR050184 A1 AR 050184A1 AR P050103099 A ARP050103099 A AR P050103099A AR P050103099 A ARP050103099 A AR P050103099A AR 050184 A1 AR050184 A1 AR 050184A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- aralkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 7
- -1 cyano, hydroxy Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 4
- 125000000732 arylene group Chemical group 0.000 abstract 3
- 125000005549 heteroarylene group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 239000002439 beta secretase inhibitor Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003540 gamma secretase inhibitor Substances 0.000 abstract 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 abstract 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 1
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente trata de inhibidores macrocíclicos de beta-secretasa. Además se revelan composiciones farmacéuticas que comprenden los compuestos de formula (1). Se describen también métodos para el tratamiento de enfermedades cognitiva o neurodegenerativas, tales como la enfermedad de Alzheimer. Adicionalmente, se describen métodos para el tratamiento de una enfermedad cognitiva o neurodegenerativa, que comprenden la administracion de una combinacion de por lo menos un compuesto de la formula (1) y por lo menos un compuesto seleccionado del grupo que consiste en inhibidores de beta-secretasa diferentes de los de formula (1); inhibidores de HMG-CoA reductasa; inhibidores de gamma-secretasa; agentes antiinflamatorios no corticoesteroides, antagonistas del receptor de N-metil-D-aspartato; inhibidores de colinesterasa; y anticuerpos antiamiloideos; a un paciente que necesita dicho tratamiento. Reivindicacion 1: Un compuesto que tiene la formula estructural (1) o una sal farmacéuticamente aceptable de dicho compuesto, donde R1 es como se muestra en los restos de formulas (2) o (3); R2 es -N(R5)C(O)R4- o un anillo heterociclileno; R3 es arileno, heteroarileno, heterociclileno o cicloalquileno; R4 es arileno, heteroarileno, heterociclileno o cicloalquileno; R5 es H, alquilo, arilo, heteroarilo o cicloalquilo; R6 y R7 se seleccionan de manera independiente de H, -OH, alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, arilo, heteroarilo, aralquilo, heteroaralquilo, aralcoxi, heteroaralcoxi y alcoxi, con la condicion de que cuando R6 y R7 son -OH, aralcoxi, heteroaralcoxi y alcoxi, R6 y R7 no están unidos a un C de anillo adyacente a un N de anillo; R8 es H, alquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, aralquilo, heteroaralquilo, heterociclilo, heterociclilalquilo, -C(O)R9, -C(O)OR12, , -S(O)R9, -S(O2)R9 o -CN; con la condicion de que cuando Y es =O, R8 no puede ser -C(O)R9, -C(O)OR12, -S(O)R9, --S(O2)R9 o - CN; R9 es H, alquilo, cicloalquilo, arilo, heteroarilo, cicloalquilalquilo, aralquilo, heteroaralquilo, heterociclilo, heterociclilalquilo, alquenilo, alquinilo o -N(R10)(R11); R10 y R11 se seleccionan de manera independiente del grupo que consiste en h, alquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, heterociclilo, aralquilo, heteroaralquilo, heterociclilalquilo, alquenilo y alquinilo; o R10 y R11 junto con el N al que están unidos forman un anillo heterociclilo de 3 a 7 miembros; R12 es alquilo, cicloalquilo, arilo, heteroarilo, cicloalquilalquilo, aralquilo, heteroaralquilo, heterociclilo, heterociclilalquilo, alquenilo o alquinilo; X es O, S, C(R5), o NH; Y es =O, o (H,H); m es 1, 2 o 3; n es 0, 1, 2, o 3 y o es 0, 1, 2 o 3; donde cada alquilo está opcionalmente sustituido con 1 a 3 porciones seleccionadas del grupo que consiste en halo, arilo, cicloalquilo, ciano, hidroxi, alcoxi, alquiltio, amino, -NH(alquilo), -NH(cicloalquilo), -N(alquilo)2, carboxi y - C(O)O-alquilo; y donde cada arileno, heteroarileno, heterociclilo, heterociclilalquilo, heterociclileno, cicloalquileno, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, heterociclilo, aralquilo, heteroaralquilo, aralcoxi o heteroaralcoxi está opcionalmente sustituido con 1 a 4 porciones seleccionadas del grupo que consiste en -CF3, alquilo, alquenilo, alquinilo, arilo, heteroarilo, aralquilo, alquilarilo, heteroaralquilo, heteroarilalquenilo, heteroarilalquinilo, alquilheteroarilo, hidroxi, hidroxialquilo, alcoxi, ariloxi, aralcoxi, acilo, aroílo, halo, nitro, ciano, carboxi, alcoxicarbonilo, ariloxicarbonilo, aralcoxicarbonilo, alquilsulfonilo, arilsulfonilo, heteroarilsulfonilo, alquiltio, ariltio, heteroariltio, aralquiltio, heteroaralquiltio, cicloalquilo, heterociclilo, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alquilo), Y1Y2N-, Y1Y2N-alquilo-, Y1Y2NC(O)-, Y1Y2NSO2- y -SO2NY1Y2, en donde Y1 e Y2 pueden ser iguales o diferentes, y se seleccionan de manera independiente del grupo que consiste en H, alquilo, arilo, cicloalquilo, y aralquilo, con la condicion de que cicloalquileno y heterociclileno pueden estar sustituidos con =O.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59189904P | 2004-07-28 | 2004-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050184A1 true AR050184A1 (es) | 2006-10-04 |
Family
ID=35106859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103099A AR050184A1 (es) | 2004-07-28 | 2005-07-26 | Inhibidores macrociclicos de beta-secretasa |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7652003B2 (es) |
| EP (1) | EP1781644B1 (es) |
| JP (1) | JP2008508289A (es) |
| CN (1) | CN101027297B (es) |
| AR (1) | AR050184A1 (es) |
| AT (1) | ATE396990T1 (es) |
| CA (1) | CA2575340A1 (es) |
| DE (1) | DE602005007245D1 (es) |
| ES (1) | ES2306200T3 (es) |
| MX (1) | MX2007001102A (es) |
| TW (1) | TWI297337B (es) |
| WO (1) | WO2006014944A1 (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) * | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| GB0500683D0 (en) * | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| BRPI0606636A2 (pt) * | 2005-01-13 | 2009-07-07 | Novartis Ag | compostos macrocìclicos úteis como inibidores de bace |
| SG162790A1 (en) | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
| ATE482214T1 (de) | 2005-06-14 | 2010-10-15 | Schering Corp | Aspartylproteasehemmer |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| US8168641B2 (en) | 2006-06-12 | 2012-05-01 | Schering Corporation | Aspartyl protease inhibitors |
| CA2656869A1 (en) * | 2006-07-20 | 2008-01-24 | Novartis Ag | Macrocyclic lactams |
| JP2010505833A (ja) | 2006-10-06 | 2010-02-25 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病を治療するためのマクロ環式スピロピペリジンβ−セクレターゼ阻害剤 |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| MX2009006228A (es) | 2006-12-12 | 2009-06-22 | Schering Corp | Inhibidores de aspartil proteasa. |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| CN101848897A (zh) | 2007-09-06 | 2010-09-29 | 先灵公司 | γ分泌酶调节剂 |
| WO2009061699A1 (en) | 2007-11-05 | 2009-05-14 | Schering Corporation | Gamma secretase modulators |
| CA2708300A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
| AU2009239536C1 (en) | 2008-04-22 | 2012-12-13 | Merck Sharp & Dohme Corp. | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
| AU2009314049B2 (en) | 2008-11-13 | 2015-03-05 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| EP2379566A2 (en) | 2008-12-22 | 2011-10-26 | Schering Corporation | Gamma secretase modulators |
| JP2012513399A (ja) | 2008-12-22 | 2012-06-14 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
| WO2010147975A1 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| EP2443118A1 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
| WO2010147969A2 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| BR112012008346B1 (pt) | 2009-09-11 | 2021-12-21 | Vivoryon Therapeutics N.V. | Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica |
| EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9181236B2 (en) | 2011-08-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
| CN104270945B (zh) | 2012-03-19 | 2017-03-29 | 巴克老龄化研究所 | App特异性bace抑制剂(asbi)及其用途 |
| WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
| EP2908824B1 (en) | 2012-10-17 | 2018-05-02 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| CN105175488A (zh) * | 2015-09-07 | 2015-12-23 | 西北农林科技大学 | 一种具有抗老年痴呆症活性的化合物及其制备方法 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003842A1 (en) | 1987-10-21 | 1989-05-05 | The Upjohn Company | Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety |
| DE60116313T2 (de) | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| ATE323084T1 (de) * | 2001-06-12 | 2006-04-15 | Elan Pharm Inc | Für die behandlung von alzheimer krankheit geeignete makrocyclen |
| US20040171614A1 (en) * | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| ATE443043T1 (de) * | 2002-11-12 | 2009-10-15 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| CA2512111A1 (en) * | 2003-01-07 | 2004-07-29 | Merck And Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
| ATE444962T1 (de) * | 2004-06-16 | 2009-10-15 | Wyeth Corp | Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung |
| JP2008503460A (ja) * | 2004-06-16 | 2008-02-07 | ワイス | β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン |
| JP2009500329A (ja) | 2005-06-30 | 2009-01-08 | ワイス | アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用 |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| AU2006294620A1 (en) | 2005-09-26 | 2007-04-05 | Wyeth | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
| CN101460480A (zh) | 2006-04-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
-
2005
- 2005-07-26 AT AT05776414T patent/ATE396990T1/de not_active IP Right Cessation
- 2005-07-26 CN CN2005800323948A patent/CN101027297B/zh not_active Expired - Fee Related
- 2005-07-26 EP EP05776414A patent/EP1781644B1/en not_active Expired - Lifetime
- 2005-07-26 US US11/189,346 patent/US7652003B2/en not_active Expired - Lifetime
- 2005-07-26 ES ES05776414T patent/ES2306200T3/es not_active Expired - Lifetime
- 2005-07-26 MX MX2007001102A patent/MX2007001102A/es active IP Right Grant
- 2005-07-26 WO PCT/US2005/026468 patent/WO2006014944A1/en not_active Ceased
- 2005-07-26 AR ARP050103099A patent/AR050184A1/es not_active Application Discontinuation
- 2005-07-26 DE DE602005007245T patent/DE602005007245D1/de not_active Expired - Lifetime
- 2005-07-26 CA CA002575340A patent/CA2575340A1/en not_active Abandoned
- 2005-07-26 JP JP2007523724A patent/JP2008508289A/ja active Pending
- 2005-07-27 TW TW094125432A patent/TWI297337B/zh not_active IP Right Cessation
-
2009
- 2009-10-01 US US12/571,840 patent/US8012953B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007001102A (es) | 2007-04-13 |
| US20060040948A1 (en) | 2006-02-23 |
| ES2306200T3 (es) | 2008-11-01 |
| DE602005007245D1 (es) | 2008-07-10 |
| US20100178294A1 (en) | 2010-07-15 |
| TWI297337B (en) | 2008-06-01 |
| TW200607807A (en) | 2006-03-01 |
| ATE396990T1 (de) | 2008-06-15 |
| CN101027297A (zh) | 2007-08-29 |
| US7652003B2 (en) | 2010-01-26 |
| JP2008508289A (ja) | 2008-03-21 |
| EP1781644B1 (en) | 2008-05-28 |
| HK1102328A1 (en) | 2007-11-16 |
| US8012953B2 (en) | 2011-09-06 |
| CA2575340A1 (en) | 2006-02-09 |
| CN101027297B (zh) | 2010-09-08 |
| EP1781644A1 (en) | 2007-05-09 |
| WO2006014944A1 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050184A1 (es) | Inhibidores macrociclicos de beta-secretasa | |
| AR049726A1 (es) | Amidas sustituidas inhibidoras de beta secretasa | |
| ES2809974T3 (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas | |
| Ruchelman et al. | 11H-Isoquino [4, 3-c] cinnolin-12-ones: novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity | |
| US11124516B2 (en) | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| JP5584626B2 (ja) | ２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用 | |
| JP5584627B2 (ja) | 置換されたシクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用 | |
| EA006815B1 (ru) | Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7 | |
| PT94806A (pt) | Processo para a preparacao de agentes antipsicoticos espirociclicos | |
| JP2009513495A (ja) | 癌の治療において有効な新規のピロロジヒドロイソキノリン | |
| CA3109617A1 (en) | Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use | |
| EP1996550A2 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
| JP2015529252A (ja) | フルオロアルキル−１，４−ベンゾジアゼピノン化合物 | |
| AU2021227907A1 (en) | Potent and selective degraders of ALK | |
| KR20020089372A (ko) | 알파-2 길항제로서의 퀴놀린 유도체 | |
| JP2009539936A (ja) | ピラゾロピリミドン | |
| JP2002541144A (ja) | 医薬的に活性のある化合物及びその使用方法 | |
| AR032475A1 (es) | Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende | |
| ES2255483T3 (es) | 6-arilfenantridinas con actividad inhibidora de pde-iv. | |
| CA3134491A1 (en) | Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use | |
| Faist et al. | New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds | |
| JP5575663B2 (ja) | 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用 | |
| JP2011519921A (ja) | テトラヒドロピラゾロ［１，５−ａ］ピリド−ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用 | |
| JP2018522058A (ja) | 化合物 | |
| JP2018516265A (ja) | 抗寄生虫剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |